Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?
Mené sur 578 patients atteints d'une leucémie lymphocytaire chronique ou d'un lymphome lymphocytaire à petits lymphocytes, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'ibrutinib à un traitement combinant bendamustine et rituximab
The current gold standard for most patients with chronic lymphocytic leukaemia is chemoimmunotherapy with anti-CD20 monoclonal antibodies and cytotoxic drugs. The combination of bendamustine with rituximab is commonly used in patients with previously untreated and relapsed or refractory disease. Moreover, the recent approval of the kinase inhibitors ibrutinib and idelalisib represents a substantial therapeutic advance in chronic lymphocytic leukaemia. Both agents have demonstrated a good safety profile and promising clinical efficacy.
The Lancet Oncology , commentaire, 2014